BPT567, a first-in-class PD1-IL18 immunoconjugate designed to enable cis-signaling and preferentially activate intratumoral PD1+IL18R+ effector T cells induces potent preclinical antitumor activity SAN DIEGO and BASEL, Switzerland, April 09, 2024 (GLOBE NEWSWIRE) — Bright Peak Therapeutics, a biotechnology company developing multifunctional immunotherapies for cancer and autoimmune disease, today announced the presentation of new data characterizing […]
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.